Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-06-13T00:26:07.708Z Has data issue: false hasContentIssue false
  • English
  • Français

Galantamine beyond Alzheimer’s disease—a fact or artefact?

Published online by Cambridge University Press:  14 December 2020

Ahmed Naguy Open the ORCID record for Ahmed Naguy [Opens in a new window] ,
Khaled Husain  and
Bibi Alamiri
Ahmed Naguy*
Affiliation:
Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait
Khaled Husain
Affiliation:
Pharmacy Department, Kuwait Centre for Mental Health (KCMH), Jamal Abdul-Nassir St., Shuwaikh, State of Kuwait
Bibi Alamiri
Affiliation:
Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait
*
*Author for correspondence: Ahmed Naguy, Email: ahmednagy@hotmail.co.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

Galantamine is US-Food and Drug Administration FDA-approved for mild-to-moderate Alzheimer’s disease. However, its unique pharmacological portfolio speaks to the idea of a pluripotent agent with a broad therapeutic potential. Here, authors briefly discuss these off-label clinical indications synthesizing the extant evidence.

Keywords

Clinical usesgalantaminepharmacology
Type
Perspective
Information
CNS Spectrums , Volume 27 , Issue 3 , June 2022 , pp. 268 - 271
Copyright
© The Author(s), 2020. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Rogawski, MA. What is the rationale for new treatment strategies in Alzheimer’s disease? CNS Spectr. 2004;9(S5):6–21, 31.CrossRefGoogle ScholarPubMed
Scott, LJ, Goa, KL. Galantamine: a review of its use in Alzheimer’s disease. Drugs. 2000;60(5):1095–1122.CrossRefGoogle ScholarPubMed
Dengiz, AN, Kershaw, P. The clinical efficacy and safety of galantamine in the treatment of Alzheimer’s disease. CNS Spectr. 2004;9(5):377–392.CrossRefGoogle ScholarPubMed
Villarroya, M, Garcia, AG, Marco-Contelles, J, et al. An update on the pharmacology of galantamine. Expert Opin Investig Drugs. 2007;16(12):1987–1998.CrossRefGoogle ScholarPubMed
Baakman, AC, Hart, E, Kay, DG, et al. First in human study with a prodrug of galantamine: improved benefit-risk ratio? Alzheimers Dement (NY). 2016;2(1):13–22.CrossRefGoogle ScholarPubMed
Samanta, MK, Wilson, B, Santhi, K, et al. Alzheimer disease and its management: a review. Am J Ther. 2006;13(6):516–526.CrossRefGoogle ScholarPubMed
Kaufer, DI, Borson, S, Kershaw, P, et al. Reduction of caregiver burden in Alzheimer’s disease by treatment with galantamine. CNS Spectr. 2005;10(6):481–488.CrossRefGoogle ScholarPubMed
Dan-Dan, L, Ya-Hong, Z, Wei, Z, et al. Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease. Front Neurosci. 2019;13:472 Google Scholar
Craig, D, Birks, J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev. 2006;25(1):CD004746 Google Scholar
Biederman, J, Mick, E, Faraone, S, et al. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2006;26:163–166.CrossRefGoogle ScholarPubMed
Hertzman, M. Galantamine in the treatment of adult autism: a report of three clinical cases. Int J Psychiatry Med. 2003;33(4):395–398.CrossRefGoogle ScholarPubMed
Nicolson, R, Craven-Thuss, B, Smith, J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006;16(5):621–629.CrossRefGoogle ScholarPubMed
Ghaleiah, A, Ghyasvand, M, Mohammadi, MR, et al. Galantamine efficacy and tolerability as an augmentative therapy in autistic children: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2013;28(7):677–685.CrossRefGoogle Scholar
Veronese, N, Solmi, M, Luchini, C, et al. Acetylcholinesterase inhibitors and memantine in bipolar disorder: a systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions. J Affect Disord. 2016;197:268–280.CrossRefGoogle ScholarPubMed
Iosifescu, DV, Moore, CM, Deckersbach, T, et al. Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. CNS Neurosci Ther. 2009;15(4):309–319.CrossRefGoogle ScholarPubMed
Ghaemi, SN, Gilmer, WS, Dunn, RT, et al. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J Clin Psychopharmacol. 2009;29(3):291–295.CrossRefGoogle ScholarPubMed
Sanches, M, Bauer, IE, Galvez, JF, et al. The management of cognitive impairment in bipolar disorder: current status and perspectives. Am J Ther. 2015;22(6):477–486.CrossRefGoogle Scholar
Philpot, RM, Ficken, M, Johns, BE, et al. Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors. Cancer Chemothe Pharmacol. 2019;84(3):579–589.CrossRefGoogle ScholarPubMed
Tsvetkova, D, Obreshkova, D, Zheleva-Dimitrova, D, et al. Antioxidant activity of galantamine and some of its derivatives. Curr Med Chem. 2013;20(36):4595–4608.CrossRefGoogle ScholarPubMed
Simoes de Souza, FM, Busquet, N, Blatner, M, et al. Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome. Sci Rep. 2011;1:137 CrossRefGoogle Scholar
Pereira, EFR, Aracava, Y, Alkondon, M, et al. Molecular and cellular actions of galantamine: clinical implications for treatment of organophosphorus poisoning. J Mol Neurosci. 2010;40(1–2):196–203.CrossRefGoogle ScholarPubMed
Koola, MM. Potential role of antipsychotic-galantamine-memantine combination in the treatment of positive, cognitive, and negative symptoms of schizophrenia. Mol Neuropsychiatry. 2018;4(3):134–148.CrossRefGoogle ScholarPubMed
MacLean, RR, Waters, AJ, Brede, E, et al. Effects of galantamine on smoking behavior and cognitive performance in treatment-seeking smokers prior to a quit attempt. Hum Psychopharmacol. 2018;33(4):e2665 CrossRefGoogle ScholarPubMed
Sofuoglo, M, Herman, AI, Li, Y, et al. Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette: a preliminary report. Psychopharmacology (Berl). 2012;224(3):413–420.CrossRefGoogle Scholar
Diehl, A, Nakovics, H, Croissant, B, et al. Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. Int J Clin Pharmacol Ther. 2006;44(12):614–622.CrossRefGoogle ScholarPubMed
Hong, JM, Shin, DH, Lim, TS, et al. Galantamine administration in chronic poststroke aphasia. J Neurol Neurosurg Psychiatry. 2012;83(7):675–680.CrossRefGoogle Scholar
Lorrio, S, Sobrado, M, Arias, E, et al. Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J Pharmacol Exp Ther. 2007;322(2):591–599.CrossRefGoogle ScholarPubMed
Zhao, J, Hylin, MJ, Kobori, N, et al. Post-injury administration of galantamine reduces traumatic brain injury pathology and improves outcome. J Neurotrauma. 2018;35(2):362–374.CrossRefGoogle ScholarPubMed
Koola, MM. Galantamine-memantine combination for cognitive impairments due to electroconvulsive therapy, traumatic brain injury, and neurologic and psychiatric disorders: kynurenic acid and mismatch negativity target engagement. Prim Care Companion CNS Disord. 2018;20(2):17nr02235 CrossRefGoogle ScholarPubMed
Anghinah, R, Oliveira de Amorim, RL, Paiva, WS, et al. Traumatic brain injury pharmacological treatment: recommendations. Arq Neuropsiquiatr. 2018;76(2):100–103.CrossRefGoogle ScholarPubMed